4523 Stock Overview
Engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 3/6 |
Past Performance | 1/6 |
Financial Health | 6/6 |
Dividends | 3/6 |
Eisai Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥6,478.00 |
52 Week High | JP¥9,614.00 |
52 Week Low | JP¥5,795.00 |
Beta | -0.042 |
11 Month Change | -4.28% |
3 Month Change | 5.87% |
1 Year Change | -30.95% |
33 Year Change | -39.43% |
5 Year Change | 6.67% |
Change since IPO | 297.77% |
Recent News & Updates
Shareholder Returns
4523 | JP Pharmaceuticals | JP Market | |
---|---|---|---|
7D | -1.7% | 3.6% | 2.4% |
1Y | -31.0% | 16.4% | 24.6% |
Return vs Industry: 4523 underperformed the JP Pharmaceuticals industry which returned 16.4% over the past year.
Return vs Market: 4523 underperformed the JP Market which returned 24.6% over the past year.
Price Volatility
4523 volatility | |
---|---|
4523 Average Weekly Movement | 3.6% |
Pharmaceuticals Industry Average Movement | 3.7% |
Market Average Movement | 3.8% |
10% most volatile stocks in JP Market | 7.3% |
10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 4523 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4523's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1941 | 11,067 | Haruo Naito | www.eisai.co.jp |
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2.
Eisai Co., Ltd. Fundamentals Summary
4523 fundamental statistics | |
---|---|
Market cap | JP¥1.85t |
Earnings (TTM) | JP¥42.41b |
Revenue (TTM) | JP¥741.75b |
43.7x
P/E Ratio2.5x
P/S RatioIs 4523 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4523 income statement (TTM) | |
---|---|
Revenue | JP¥741.75b |
Cost of Revenue | JP¥155.33b |
Gross Profit | JP¥586.42b |
Other Expenses | JP¥544.01b |
Earnings | JP¥42.41b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 02, 2024
Earnings per share (EPS) | 148.35 |
Gross Margin | 79.06% |
Net Profit Margin | 5.72% |
Debt/Equity Ratio | 17.7% |
How did 4523 perform over the long term?
See historical performance and comparison